Related Experiment Videos
PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling
1Department of Adult Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Cancer Treatment and Research
|March 5, 2003
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Context-dependent synthetic lethality - an emerging precision therapeutic approach.
Nature reviews. Cancer·2026
Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.
Cell chemical biology·2026
RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.
Molecular cancer research : MCR·2025
Targeting KIT With Antibody-Drug Conjugates in Chromophobe Renal Cell Carcinoma.
Clinical genitourinary cancer·2025
Clinical Trials and Translational Advances in Metabolic Targeting.
Cancer treatment and research·2026
Tools and Technologies for Studying Cancer Metabolism.
Cancer treatment and research·2026
Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.
Cancer treatment and research·2026
Biomarkers of Cancer Metabolism and Therapeutic Response.
Cancer treatment and research·2026
Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.
Cancer treatment and research·2026
Metabolic Reprogramming in Cancer Stem Cells.
Cancer treatment and research·2026
Programmed cell death in degenerative skeletal diseases: molecular crosstalk and combinatorial therapeutic strategies.
Frontiers in cell and developmental biology·2026
Modeling Risk Group 4 virus infection and antiviral treatment in microfluidic lung organ-on-chips in maximum containment laboratories.
bioRxiv : the preprint server for biology·2026
Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment.
The Annals of pharmacotherapy·2026
Efficacy and Safety of Tofacitinib Versus Placebo in Patients With Early-Grade Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial.
International journal of rheumatic diseases·2026